Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05832489 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

EEG-MRI Imaging of Methylphenidate Effects in Adult ADHD and Attentional Symptoms in Mood Disorders

Study acronym: ImAteM-TDA
StatusRecruiting
PhasePhase 3
Started2024-02-26
View on ClinicalTrials.gov ↗

Amendment history

2026-08-20
minor
Study Status v3
Re-verified, no change to tracked fields
2024-07-29
minor
Study Status, Study Description, Arms and Interventions, Outcome Measures, Eligibility v2
Primary completion date2027-04→2027-05
Completion date2027-04→2027-05
Eligibility criteria+93 characters
[...] in care under restraint Subject under safeguard of justice SubjectIncompetent undersubject (subject to a legal protection measure: curatorship, guardianship, orfuture trusteeshipprotection mandate, family habilitation) Impossibility to give informed information about the subjec [...]
Study descriptionrevised
[...] during the experimental sessions. During imaging session 1 (73 to 3060 days from inclusion): Patients usually taking methylphenida [...] mplete self-questionnaires. During imaging session 2 (14 to 6090 days from inclusion): the same procedure is done again. Pat [...] placebo during imaging session 1) 30-60 minutes before MRI. IRMMRI and EEG procedure are the same. fMRI imaging includes rest [...]
2024-03-15
notable
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2026-12-30→2027-04
Completion date2026-12-30→2027-04
Start dateestimated 2023-10-01→confirmed 2024-02-26
Study sitesdetails revised at 1 of 1 site
2023-04-14
minor
Original filing
Attention Deficit Hyperactivity Disorder (ADHD) in adults is a common psychiatric disorder, with important consequences in terms of quality of life, mental health (associated disorders and poorer response to treatment), family life, risk of accidents; with a consequent cost for society. Adult ADHD is frequently associated with psychiatric co-morbidities, and notably associated with mood disorders (major depressive disorder or bipolar disorder) in about 50% of cases. The diagnosis of ADHD in adults is made in patients with an attentional complaint (pure ADHD or ADHD-P), but also very often in the management of a comorbid mood disorder (ADHD associated with mood disorder, or ADHD-MD). In this case, the ADHD had no impact during childhood and adolescence. Medication management is well established for ADHD-P, and medication is based on methylphenidate, which has a rapid and significant effect on attentional symptoms and impulsivity. However, in the case of ADHD-HD, there is little evidence of treatment efficacy and the mechanisms of action of methylphenidate at the brain level are poorly understood. The aim of the study is to determine the neural mechanisms of the effect of methylphenidate, using functional MRI and EEG, in ADHD-P and ADHD-HD patients, and to compare them to healthy subjects. A single dose allows us to observe effects that are then persistent with repeated doses. The aim is to determine, by means of a biomarker, whether methylphenidate treatment responds to the same mechanisms in the different groups and would be relevant in ADHD-P as in ADHD-HD. Main objective: To determine whether methylphenidate impacts differently on brain circuits associated with cognitive functions in the two clinical populations studied (adult ADHD patients and patients with post mood disorder attentional deficit) and in comparison to controls. Secondary objectives: 1. To determine the effect of methylphenidate on baseline brain flow in the two clinical populations and in controls (healthy subjects). 2. To determine whether methylphenidate has a different impact on cognitive performance in the two clinical populations studied and in comparison to controls (healthy subjects). 3. To confirm the effect of methylphenidate on the maintenance of cortical arousal. 4. To distinguish the brain networks impacted by methylphenidate (maintenance of attention or inhibition) with MRI and EEG.
Trial Details
NCT Number NCT05832489
Lead Sponsor University Hospital, Strasbourg, France
Conditions Adult ADHD, Adult-onset ADHD With Mood Disorder
Enrollment 80 participants
Start Date 2024-02-26
Primary Completion 2027-05 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-21